When are ELI LILLY & Co (LLY) earnings?

AlphaOS tracks the latest reported quarter and upcoming earnings context for ELI LILLY & Co (LLY) on the earnings intelligence page. Dates and figures update as IR and filing data land — always verify against the company's official calendar.

Did LLY beat earnings estimates?

AlphaOS surfaces beat/miss versus consensus where available, alongside YoY growth and guidance context for ELI LILLY & Co. Open the earnings tab for the structured scorecard and AI-assisted analysis.

Where can I read LLY earnings analysis?

AlphaOS publishes structured earnings intelligence for ELI LILLY & Co (LLY) — results, guidance, and connected research — for education only, not investment advice.

LLY

ELI LILLY & Co

Healthcare · Pharmaceuticals

$1,180.16Aug 14, 2026

AI confidence 59% · prior close shown (market closed)

Investment Snapshot

78% confidence

Why it matters

ELI LILLY & Co shows accelerating business momentum based on AlphaOS pipeline evidence, with weak management execution.

Why it matters: Revenue +48% YoY in Q2 FY2026.

Watch: EPS significantly below estimate raises questions about near-term cost pressures or revenue timing.

TrajectoryAccelerating

ExecutionWeak

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

Revenue +48% YoY in Q2 FY2026
EPS Below Estimate
Revenue Data Unavailable
Guidance Maintained
Acquisition of Ajax Therapeutics
Acquisition of Kelonia Therapeutics
Acquisition of Centessa Pharmaceuticals

Risks

EPS significantly below estimate raises questions about near-term cost pressures or revenue timing · medium
Absence of revenue data limits ability to assess Mounjaro and Zepbound commercial trajectory · medium

Priorities

2025 reported EPS guidance · In progress
2025 revenue guidance · In progress

Supporting evidence

LedgerNo revenue data available, preventing assessment of Mounjaro and Zepbound commercial performance
LedgerStrong quarter based on: Diluted EPS of $0.03 fell sharply below the $0.14 estimate, indicating near-term profitability pressure · No revenue data available, preventing assessment of Mounjaro and Zepb…
LedgerRevenue +48% YoY (Q2 FY2026)

EventEPS Below Estimate
EventRevenue Data Unavailable
EventGuidance Maintained
EventExpands Lilly's portfolio and capabilities.
EventExpands Lilly's portfolio and capabilities.
EventExpands Lilly's portfolio and capabilities.
InitiativeGuidance updated downwards, indicating potential challenges or revised expectations.
InitiativeGuidance remains unchanged, suggesting stable revenue expectations.
EventEPS significantly below estimate raises questions about near-term cost pressures or revenue timing
EventAbsence of revenue data limits ability to assess Mounjaro and Zepbound commercial trajectory

Pipeline evidence · 0d ago

Latest earnings · Q2 2026

Full LLY earnings analysis

Reported figures for ELI LILLY & Co — research only, not investment advice.

Revenue YoY: +47.6%
EPS YoY: +26.2%
Intel score: 86

Theme: GLP-1 Franchise — Mounjaro & Zepbound

Latest Intelligence

Updated August 15, 2026

What happened recently for ELI LILLY & Co (LLY) — events, not interpretation.

Event: Reported Q2 2026 revenue +48% YoY.
Also: Last session August 14, 2026 at $1,180.16.
Source: Q2 2026 earnings

Research & analysis only — not investment advice.

Loading earnings intelligence…

ELI LILLY & Co (LLY)

Healthcare · Pharmaceuticals

Investment Snapshot above is the primary AlphaOS analysis for ELI LILLY & Co — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:: Healthcare
Industry:: Pharmaceuticals
Market cap:: $1.11T
Revenue:: $65.18B

LLY earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Related & Connected

Competitors

NOVO NORDISK A S95% confidencecompetitor

Opening stock page...

Fetching company snapshot, pricing, and intelligence.

LLY

Investment Snapshot

Why it matters

Key signals

Risks

Priorities

Supporting evidence

Latest earnings · Q2 2026

Latest Intelligence

ELI LILLY & Co (LLY)

Key facts

Related & Connected

Competitors

Related

LLY

Investment Snapshot

Why it matters

Key signals

Risks

Priorities

Supporting evidence

Latest earnings · Q2 2026

Latest Intelligence

ELI LILLY & Co (LLY)

Key facts

Related & Connected

Competitors

Related

Connected intelligence

Compare